The HCPLive Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for C difficile, IBS and IBD, Crohn's disease, and more.
April 22nd 2024
Announced on April 18, the approval is based on the VISIBLE 2 trial and comes less than 7 months after the approval of SC vedolizumab in ulcerative colitis.
Show Me the Data: Bridging Clinical Gaps in Later Lines of Metastatic CRC… It’s Easy as VEGFR1, 2, 3!
April 17, 2024
View More
9th Annual School of Gastrointestinal Oncology® (SOGO®)
View More
Medical Crossfire®: Critical Questions on Diagnosis, Sequencing, and Selection of Systemic and Radioligand Therapy Options for Patients with GEP-NETs
View More
"REEL" Time Patient Counseling™: Integrating Biosimilars into the Clinical Conversation
View More
Rapid Oncology Abstract Review®: Key Updates in Gastrointestinal Cancers from the ASCO Annual Meeting
View More
Medical Crossfire®: Bridging Precision Medicine Techniques and Emerging Treatments in Metastatic Colorectal Cancer
View More
Community Practice Connections™: 8th Annual School of Gastrointestinal Oncology®
View More
Burst CME: Incorporating the Latest Updates in IBS Treatment into Your Practice
View More
Advancing Care in Erosive Esophagitis: Towards a Path of Complete Healing
View More
Oncology Town Hall: Live Report from Barcelona for Advances in the Treatment of GI Cancers
View More
Cancer Summaries and Commentaries™: Clinical Updates in RCC from Chicago
View More
Collaborating Across the Continuum™: The Role of Multidisciplinary Care in the Management of Patients with Exocrine Pancreatic Insufficiency
View More
2024 Miami International Symposium of Gastrointestinal Oncology (ISGIO)
October 11-12, 2024
Register Now!
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Community Practice Connections™: 20th Annual Meeting of the International Society of Gastrointestinal Oncology®
View More
Working Group: Streamlining the Pathway from Diagnosis to Treatment in Inflammatory Bowel Disease
View More
Advances In™: The Evolving Role of VEGFR in the Treatment of Refractory mCRC
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Show Me the Data: Bridging Clinical Gaps in Later Lines of Metastatic CRC… It’s Easy as VEGFR1, 2, 3!
View More
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
Tissue Stewardship and the Evolving Role of Genomic Alterations in Providing Precision NSCLC Care
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
SEQUENCE: Comparing Risankizumab to Ustekinumab in Crohn’s Disease
December 6th 2023Ustekinumab is currently the only anti-interleukin therapy approved for the treatment of ulcerative colitis, but given the superior performance of risankizumab in CD patients, it will be interesting to see data regarding its efficacy in UC.
ODESSA-UC Study Compares Dose Escalation in Vedolizumab, AntiTNF-α for Ulcerative Colitis
December 2nd 2023Results showed patients treated with vedolizumab experienced less dose escalation and were at a decreased risk of requiring dose escalation compared to patients treated with adalimumab and infliximab.
Black Patients Receive Less C Diff Tests Despite Similar Positivity Rates to White Patients
November 27th 2023A retrospective cohort study of inpatient encounters from 3 hospitals in the Duke University Health System showed greater rates of testing among White patients compared to Black and NWNB patients.
Study Identifies Predictors of Fibromyalgia, Chronic Fatigue in IBS Patients
October 31st 2023A retrospective analysis of data from the US National Inpatient Sample revealed the prevalence of fibromyalgia and chronic fatigue syndrome was significantly increased in patients with IBS compared to those without IBS.
Guselkumab Leads to Rapid Ulcerative Colitis Symptom Improvement
Induction treatment with guselkumab resulted in a rapid onset of efficacy, beginning at week 1 and increasing over time to week 12, for patients with refractory moderately to severely active ulcerative colitis.